MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

Authors:
  • MDMeletios A. Dimopoulos
    Meletios A. Dimopoulos
  • PSPieter Sonneveld
    Pieter Sonneveld
  • PRPaula Rodriguez-Otero
    Paula Rodriguez-Otero
  • HQHang Quach
    Hang Quach
  • PHP. Joy Ho
    P. Joy Ho
  • MBMeral Beksac
    Meral Beksac
  • CHCyrille Hulin
    Cyrille Hulin
  • EAElisabetta Antonioli
    Elisabetta Antonioli
  • XLXavier Leleu
    Xavier Leleu
  • SMSilvia Mangiacavalli
    Silvia Mangiacavalli
  • APAurore Perrot
    Aurore Perrot
  • MCMichele Cavo
    Michele Cavo

Abstract
No abstract available